Trial NCT04699461

View at ClinicalTrials.gov 
Org. Study IDs: ADCT 402-202
Secondary IDs: 2020-003695-40

Last trial update was posted on 2023-10-23

MeSH Interventions

Idelalisib Loncastuximab tesirine

MeSH Conditions

Lymphoma Lymphoma, Follicular

Other Conditions

Refractory Follicular Lymphoma Relapsed Follicular Lymphoma

Stopping Reasons

Administrative decision (not due to safety reason)

Limitations And Caveats

The study was terminated (administrative decision) by the sponsor following the withdrawal of idelalisib from the US market for the relapsed FL indication (i.e., not due to any safety reasons emerging from this study).

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID